Acute Myeloid Leukemia

Researchers identify potential new leukemia drug target

New treatment options are badly needed for acute myeloid leukemia, a relatively rare form of cancer. The malignancy begins in the bone marrow, and from there can spread rapidly to the bloodstream, depriving the body of the ...

Oct 22, 2015
popularity14 comments 0

Study identifies leukemia tumor suppressor

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking ...

Sep 24, 2015
popularity143 comments 0

Staying one step ahead of cancer cells

BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials. In a study published in Nature today, a team of researchers at the Research Institute of Molecular ...

Sep 15, 2015
popularity10 comments 0

Older cancer patients heavily use health care services

(HealthDay)—Older patients with acute myeloid leukemia (AML) are intense users of health care services and rarely use palliative care and hospice services, according to a study published in the August issue of Cancer.

Sep 02, 2015
popularity20 comments 0

New leukemia gene stops blood cells 'growing up'

Scientists have identified a gene - FOXC1 - that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukaemia (AML) patients, according to a Cancer Research UK study published in the journal Cancer ...

Sep 14, 2015
popularity92 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

New target could eliminate lurking cancer stem cells

Scientists from Trinity College Dublin have identified a novel target that could help to identify 'cancer stem cells' while they are in their inactive state. The scientists could then jolt these cells into action so that ...

How can I tell if she's lying?

Sarcasm, white lies and teasing can be difficult to identify for those with certain disorders – new video inventory developed at McGill may help

Functional human liver cells grown in the lab

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. ...

Combination therapy can prevent cytostatic resistance

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...